Vanda Pharmaceuticals (NASDAQ:VNDA) Given Buy Rating at HC Wainwright

Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $20.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 273.83% from the stock’s previous close.

A number of other analysts also recently issued reports on VNDA. Wall Street Zen raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 1st. Cantor Fitzgerald cut their price objective on shares of Vanda Pharmaceuticals from $13.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, October 30th. B. Riley assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, November 5th. They set a “buy” rating and a $11.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Vanda Pharmaceuticals Trading Up 21.6%

Shares of NASDAQ VNDA opened at $5.35 on Wednesday. The stock has a market cap of $316.17 million, a PE ratio of -3.77 and a beta of 0.78. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $5.70. The company has a 50-day moving average of $4.90 and a 200 day moving average of $4.66.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Vanda Pharmaceuticals had a negative return on equity of 16.44% and a negative net margin of 39.70%.The company had revenue of $56.26 million for the quarter, compared to analyst estimates of $58.73 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Vanda Pharmaceuticals in the 1st quarter valued at approximately $875,000. GSA Capital Partners LLP raised its holdings in shares of Vanda Pharmaceuticals by 88.0% in the 1st quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company’s stock valued at $1,194,000 after buying an additional 121,797 shares during the period. XTX Topco Ltd raised its holdings in shares of Vanda Pharmaceuticals by 378.3% in the 1st quarter. XTX Topco Ltd now owns 69,329 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 54,833 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Vanda Pharmaceuticals by 13.5% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 929,644 shares of the biopharmaceutical company’s stock worth $4,267,000 after acquiring an additional 110,262 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Vanda Pharmaceuticals during the 1st quarter valued at about $72,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.